Prescriptions for Zomig nasal spray increased 23% in 2014 compared to 2013, Impax Laboratories said, helping to offset a major decrease in revenues for the Impax Pharmaceuticals division after the 2013 loss of exclusivity for Zomig tablets. Revenues dropped from $113.2 million in 2013 to $47 million for 2014.
In the fourth quarter of 2014, increased sales of Zomig nasal spray led to a rise in gross margin from 56.7% to 60% from fourth quarter 2013. Adjusted gross margin rose from 62% in the fourth quarter of 2013 to 65.5%, the company noted.
Impax acquired the rights to Zomig nasal spray from AstraZeneca in 2012.
Read the Impax press release.
